Cystatin 6蛋白在哈萨克族食管鳞癌组织中的表达及其意义

doi:10.3969/j.issn.1004-616x.2022.06.004

Abstract

Abstract: OBJECTIVE:To study expression of the cystatin 6 (CST6) protein in esophageal squamous cell carcinomas among Kazakhs,and to explore its relationship with clinicopathological parameters and prognosis. METHODS:From December 2010 to December 2020,tissues from 55 Kazakh patients who had esophagectomy at the First Affiliated Hospital of Xinjiang Medical University were collected. Expression of CST6 in cancer and corresponding paracancerous tissues was detected by immunohistochemical method. Relationships between its expression and clinicopathological features was analyzed by χ² test,Kaplan-Meier univariate analysis and COX multivariate analysis to evaluate their relationships with prognosis of esophageal cancer. RESULTS:Expression of the CST6 protein was mainly located in the cytoplasm,cell membrane and keratinized area. The levels of expression of CST6 were 36.4% in the cancer and 63.6% in the corresponding paracancerous tissues. The difference was statistically significant (χ²=9.032,P=0.003). CST6 expression was related to family history (P=0.045) and tumor differentiation (P=0.036):higher in patients with no family history of tumor and with well-differentiated tumors. Kaplan-Meier survival analysis showed that the expression was related to the survival rates of patients (P<0.05):the average survival time of patients with high CST6 expression was longer. Cox multivariant survival analysis showed that negative expression was an independent risk factor for poor prognosis. CONCLUSION:CST6 protein was significantly under-expressed in esophageal squamous cell carcinoma among Kazakh patients. The protein therefore may play a tumor suppression role and its negative expression was a risk factor for poor prognosis.

Key words: Kazakh, esophageal squamous cell carcinoma, tumor suppressor gene, CST6, prognosis

CLC Number:

R735.1

LI Ziyao, ZHANG Haiping, MADINIYET·Niyaz, JULATI·Ainiwaer, ZHANG Liwei, EDRIS·Awut. Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 429-433,438.

References

[1] 王宁, 刘硕, 杨雷, 等. 2018全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2019, 5(1):87-97.
[2] KARAMANOU M, MARKATOS K, PAPAIOANNOU T G, et al. Hallmarks in history of esophageal carcinoma[J]. J BUON, 2017, 22(4):1088-1091.
[3] CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA A Cancer J Clin, 2016, 66(2):115-132.
[4] LIN Y S, TOTSUKA Y, HE Y T, et al. Epidemiology of esophageal cancer in Japan and China[J]. J Epidemiol, 2013, 23(4):233-242.
[5] 马莉莉, 张树丽, 李琴, 等. 新疆哈萨克族食管癌与正常组织间差异表达miRNA的筛查及验证[J]. 癌变·畸变·突变, 2020, 32(1):52-56.
[6] SOTIROPOULOU G, ANISOWICZ A, SAGER R. Identifi-cation, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer[J]. J Biol Chem, 1997, 272(2):903-910.
[7] ABRAHAMSON M, BARRETT A J, SALVESEN G, et al. Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids[J]. J Biol Chem, 1986, 261(24):11282-11289.
[8] ZHANG J, SHRIDHAR R, DAI Q, et al. Cystatin m:a novel candidate tumor suppressor gene for breast cancer[J]. Cancer Res, 2004, 64(19):6957-6964.
[9] VEENA M S, LEE G, KEPPLER D, et al. Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer[J]. Genes Chromosomes Cancer, 2008, 47(9):740-754.
[10] AZIMI A, LO K, KIM J, et al. Investigating proteome changes between primary and metastatic cutaneous squamous cell carcinoma using SWATH mass spectrometry[J]. J Dermatol Sci, 2020, 99(2):119-127.
[11] LALMANACH G, KASABOVA-ARJOMAND M, LECAILLE F, et al. Cystatin M/E (cystatin 6):a Janus-faced cysteine protease inhibitor with both tumor-suppressing and tumor-promoting functions[J]. Cancers, 2021, 13(8):1877.
[12] JIN L, ZHANG Y, LI H, et al. Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis[J]. Cell Res, 2012, 22(9):1356-1373.
[13] AMIN M B, GREENE F L, EDGE S B, et al. The Eighth Edition AJCC Cancer Staging Manual:continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J]. CA A Cancer J Clin, 2017, 67(2):93-99.
[14] 刘培, 黄勇. 食管癌分子生物学的研究进展[J]. 现代医药卫生, 2007, 23(5):677-679.
[15] 孟君, 刘丽华, 单保恩. 蛋白质组学与食管癌关系的研究进展[J]. 癌变·畸变·突变, 2010, 22(6):488-490.
[16] BOMAN H G. Gene-encoded peptide antibiotics and the concept of innate immunity:an update review[J]. Scand J Immunol, 1998, 48(1):15-25.
[17] ZEEUWEN P L, VAN VLIJMEN-WILLEMS I M, JANSEN B J, et al. Cystatin M/E expression is restricted to differentiated epidermal keratinocytes and sweat glands:a new skin-specific proteinase inhibitor that is a target for cross-linking by transglutaminase[J]. J Invest Dermatol, 2001, 116(5):693-701.
[18] ZHANG J, SHRIDHAR R, DAI Q, et al. Cystatin m:a novel candidate tumor suppressor gene for breast cancer[J]. Cancer Res, 2004, 64(19):6957-6964.
[19] SHRIDHAR R, ZHANG J, SONG J, et al. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells[J]. Oncogene, 2004, 23(12):2206-2215.
[20] VIGNESWARAN N, WU J, NAGARAJ N, et al. Silencing of cystatin M in metastatic oral cancer cell line MDA-686Ln by siRNA increases cysteine proteinases and legumain activities, cell proliferation and in vitro invasion[J]. Life Sci, 2006, 78(8):898-907.
[21] KEPPLER D. Towards novel anti-cancer strategies based on cystatin function[J]. Cancer Lett, 2006, 235(2):159-176.
[22] ZEEUWEN P L J M, CHENG T, SCHALKWIJK J. The biology of cystatin M/E and its cognate target proteases[J]. J Investig Dermatol, 2009, 129(6):1327-1338.
[23] LALMANACH G, KASABOVA-ARJOMAND M, LECAILLE F, et al. Cystatin M/E (cystatin 6):a Janus-faced cysteine protease inhibitor with both tumor-suppressing and tumor-promoting functions[J]. Cancers, 2021, 13(8):1877.
[24] QIU J X, AI L B, RAMACHANDRAN C, et al. Invasion suppressor cystatin E/M (CST6):high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas[J]. Lab Invest, 2008, 88(9):910-925.
[25] KIM T Y, ZHONG S, FIELDS C R, et al. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma[J]. Cancer Res, 2006, 66(15):7490-7501.

Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YU Yunliang, WANG Lili, LI Ting, FENG Jiankai. Correlations among P2RX1,prognosis and immune cells infiltration in lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 353-360,365.
[2]	ZHANG Haizhi, WEN Xiaofen, HUANG Binliang, LIN Hui, XUE Wenwu, ZENG De, LIN Danxia. Expression and clinical significance of SLC50A1 in breast carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 373-377.
[3]	ZHANG Yuling, LIU Ditian, CHEN Chunfa. Impact of CD68 macrophage infiltration on prognosis in primary small cell esophageal carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 279-283.
[4]	WANG Xujuan, LUO Yongxin, LI Chenqiang, WANG Rujin, ZHENG Tingting. Predictive values of preoperative laboratory indices dNLR, SII and CRP/ALB on recurrences and metastases in breast cancer patient [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 284-288,323.
[5]	CUI Wenxuan, JIAO Wenjing, ZHAO Wei, DU Yanyan, TIAN Guo, ZHANG Jinyan, MA Ming. Clinical values of combined FIB, FAR and serum tumor markers in diagnosis and progression of ESCC patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 289-294,326.
[6]	LIANG Feng, ZHANG Wei, LI Fei, WANG Shengjie, DU Yujing, ZHANG Yingchun. Expressions of lncRNA CASC9 in colorectal cancer and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 110-113.
[7]	PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.
[8]	JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.
[9]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[10]	YANG Xingxiao, ZHANG Xueyuan, ZOU Naiyi, SHAN Bao'en, MA Ming, ZHU Shuchai. Effects of HMGB1 silencing on migration, invasion and radiosensitivity of esophageal squamous cell carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 327-333.
[11]	YANG Liyan, LIU Zou, HAO Jiajie, ZHANG Yu, WANG Mingrong. Study on the mechanism of nucleo-plasma translocation of p62 protein in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 338-344.
[12]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[13]	CHANG Chen, YANG Liyan, CAI Hongqing, YUAN Qing, HAO Jiajie, WANG Mingrong. Expressions and clinical implications of SERPINE1 mRNA in esophageal squamous carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 245-249.
[14]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[15]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.